Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market

BOVENAU, Germany, September 16, 2024 / Biotech Newswire / -- Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau with an official inauguration ceremony on September 13th.

The new production facility was inaugurated by Daniel Günther, Minister-President of the State of Schleswig-Holstein, Daniel Ambrock, Mayor of Bovenau, on behalf of the Gedeon Richter Group: Erik Bogsch – Lifetime Honorary Chairman, Dale Martin - Member of the Supervisory Board, Dr. Erik Bogsch – Head of the Biotechnology Business Unit and Dr. Kai Pohlmeyer, CEO and Johannes Salzbrunn, COO of Richter Biologics. Guests from local government, authorities and scientific community, together with business partners and employees of Richter BioLogics and Gedeon Richter Plc, celebrated the grand opening.

“Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics' growth strategy. With one of Richter’s largest investments in the last decade, we have positioned ourselves as a key player in meeting global market demand and supplying the global pharmaceutical industry with the highest quality biopharmaceutical products. We also increase our flexibility, one of our biggest and most valued strengths” said Dr. Kai Pohlmeyer, Managing Director at Richter BioLogics.

The cGMP facility is equipped with the latest, cutting-edge technology for clinical and large-scale commercial production and market supply of protein-based and plasmid DNA-based products.

The new multi-purpose GMP facility increases the total manufacturing area to approximately 10,000 square metres. The new 300L and 1500L production lines provide further flexibility to manufacture different products simultaneously, allowing up to 120 batches per year. Additional space is being created for future growth. The facility also includes large laboratories for analytical testing, warehousing and technical areas to optimise the flow of people and materials. By the end of 2024, the number of highly skilled local employees will have doubled to more than 400.

“This investment demonstrates a strong commitment to the future of Richter BioLogics, to innovation and to GMP manufacturing of biopharmaceuticals made in Germany and to Richter’s commitment to biological products. This new facility together with our existing facilities in Hungary provide for a fully integrated R&D and manufacturing biologics capability, allowing for further access to such medicines to patients worldwide” said Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter.